Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 13;29:101206. doi: 10.1016/j.bbrep.2022.101206

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 2 — DND1 alteration is associated with clinical features of a variety of human cancers. (A) The comparison of mutation counts in colorectal cancers between DND1 altered and unaltered groups. q = 1.126e-5; (B) The comparison of the age at the diagnosis of prostate cancer between DND1 altered and unaltered groups. q = 4.521e-6; (C) The comparison of breast (Left; q = 1.663e-4) and colorectal cancer spectrum (Right; q = 1.838e-5) between DND1 altered and unaltered groups. (D) The comparison of colorectal tumor sites between DND1 altered and unaltered groups, q = 6.792e-3. (E) The comparison of overall (Left, Logrank test p-value: 2.711e-3) and progress free survivals (Right, Logrank test p-value: 1.341e-4) of prostate cancer patients between DND1 altered and unaltered groups. (F) The comparison of overall survivals of melanoma patients between DND1 altered and unaltered groups (Logrank test p-value: 4.410e-3).